TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding TScan Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 28 | 1 | 32 | +5 |
| Shares | 28.0M | 200.0K | 28.6M | +836.6K (+3.0%) |
| Value | $69.9M | $500.0K | $73.2M | +$3.82M (+5.5%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Letko, Brosseau & Associates Inc | 32,400 | $82.9K | 0.00% |
| American Century Companies Inc | 19,212 | $49.2K | 0.00% |
| Susquehanna International Group, LLP | 16,915 | $43.3K | 0.00% |
| Pale Fire Capital SE | 16,575 | $42.4K | 0.00% |
| Aries Wealth Management | 10,000 | $35.3K | 0.01% |
| Qube Research & Technologies Ltd | 2,410 | $6.17K | 0.00% |
Sold out (1)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Monashee Investment Management LLC | 400,000 | $1.00M |
Not filed for Q3 2023 yet (1)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 200,000 | $500.0K |